Melissa Johnson, MD, Tennessee Oncology

Articles

NSCLC: Final Thoughts

August 26th 2021

The discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) ends as each expert discusses their final thoughts.

NSCLC: Overcoming Challenges

August 26th 2021

Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).

ROS1-Rearranged NSCLC: Updates FromASCO

August 19th 2021

An overview of TKIs in ROS1-rearranged non–small cell lung cancer (NSCLC) and updated trial results that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting.

Preferred Treatment for ALK-Rearranged NSCLC

August 19th 2021

Experts have a discussion about their preferred treatment approach for newly diagnosed ALK-rearranged non–small cell lung cancer (NSCLC).

ALK-Rearranged NSCLC: Updates From ASCO

August 12th 2021

A summary of recent data that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for ALK-rearranged non–small cell lung cancer (NSCLC).

RET-Fusions in NSCLC: Updates From ASCO

August 12th 2021

An overview of the RET-fusion data updates that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting in non–small cell lung cancer (NSCLC).

Recent FDA-Approvals: MET Exon 14 Mutations in NSCLC

August 5th 2021

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Recent FDA-Approvals: HER2-Mutated NSCLC

August 5th 2021

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

NSCLC: Sotorasib in Practice

July 29th 2021

Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

Recent FDA-Approvals: KRAS G12C-Mutated NSCLC

July 29th 2021

An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

ASCO 2021: New Data for NSCLC Treatment Options

July 22nd 2021

Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).

NSCLC: EGFR Exon 20 Insertion Treatment Options

July 22nd 2021

Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .

Implications of Novel NSCLC Targeted Therapies

July 15th 2021

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Novel Therapies for NSCLC

July 15th 2021

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

NSCLC: FLAURA Trial Results

July 8th 2021

Edward Kim, MD, briefly summarizes results from the FLAURA trial in the treatment of previously untreated EGFR+ advanced non–small cell lung cancer (NSCLC).

First Generation TKIs in NSCLC

July 8th 2021

Melissa Johnson, MD, provides an overview of other first generation TKIs for the treatment of non–small cell lung cancer (NSCLC) in the adjuvant setting.

ADAURA Trial Results and NSCLC Treatment Decisions

July 1st 2021

Experts discuss how results from the ADAURA trial may influence treatment decisions in the adjuvant setting of non–small cell lung cancer (NSCLC).

NSCLC: ADAURA Trial Results

July 1st 2021

Ben Levy, MD, leads a discussion about the evolution of precision medicine in non–small cell lung cancer (NSCLC) beginning with an overview of the results from the ADAURA trial.